       Document 0249
 DOCN  M9640249
 TI    Ketoconazole and itraconazole susceptibility of Candida albicans
       isolated from patients infected with HIV.
 DT    9604
 AU    St-Germain G; Dion C; Espinel-Ingroff A; Ratelle J; de Repentigny L;
       Quebec Public Health Laboratory, Sainte-Anne-de-Bellevue, Canada.
 SO    J Antimicrob Chemother. 1995 Jul;36(1):109-18. Unique Identifier :
       AIDSLINE MED/96051682
 AB    Two hundred and fifty-five isolates of Candida albicans were collected
       from 93 patients infected with HIV during the course of a clinical trial
       comparing ketoconazole with itraconazole for the treatment of
       oropharyngeal or oesophageal candidosis. The susceptibility of the
       isolates to both drugs was determined by incubating 0.5-2.0 x 10(4)
       CFU/mL yeast in 0.25-16 mg/L drug in RPMI1640 buffered with MOPS for 24
       h at 35 degrees C in 5%CO2 in microtitre trays. Each plate was agitated
       before reading the optical density. The IC90, IC80 and IC50 were defined
       as the lowest drug concentration to reduce the optical density to > or =
       90%, 80% and 50% of the growth control respectively. IC90S > 0.25 mg/L
       of ketoconazole and/or itraconazole were found for 42 isolates recovered
       from 21 patients, 12 of whom had responded to treatment. IC80S > 0.25
       mg/L were found for only six of these isolates which had been recovered
       from three patients, two of whom responded well to treatment. These
       results indicate that neither the IC90 nor the IC80 are useful in
       predicting clinical resistance. None of the isolates exhibited IC50 >
       0.25 mg/L to either drug which is consistent with the low incidence of
       resistance reported for these antifungal agents.
 DE    Antifungal Agents/*THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/*DRUG THERAPY/MICROBIOLOGY  Candida albicans/*DRUG EFFECTS
       Candidiasis, Oral/*DRUG THERAPY/MICROBIOLOGY  Comparative Study
       Double-Blind Method  Human  Itraconazole/*THERAPEUTIC USE
       Ketoconazole/*THERAPEUTIC USE  Microbial Sensitivity Tests  Predictive
       Value of Tests  Prospective Studies  Support, Non-U.S. Gov't  CLINICAL
       TRIAL  JOURNAL ARTICLE  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

